On Oct. 8, 2020, The New England Journal of Medicine (NEJM) published the final results from the National Institute of Allergy and Infectious Diseasesﾒ double-blind, placebo-controlled, Phase 3 ACTT-1 trial of Gileadﾒs investigational antiviral Vekluryﾮ (remdesivir) for the treatment of adults hospitalized with mild-moderate or severe COVID-19.

The final results demonstrated that treatment with Veklury resulted in a faster time to recovery than previously reported.